ACADIA Historical Financial Ratios

ACAD Stock

USD 16.32 0.03 0.18%

ACADIA Pharmaceuticals is presently reporting on over 109 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 0.0, PTB Ratio of 12.47 or Days Sales Outstanding of 48.85 will help investors to properly organize and evaluate ACADIA Pharmaceuticals financial condition quickly.

Quick Ratio Current Ratio

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ACADIA Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For information on how to trade ACADIA Stock refer to our How to Trade ACADIA Stock guide.

About ACADIA Financial Ratios Analysis

ACADIA PharmaceuticalsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate ACADIA Pharmaceuticals investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on ACADIA financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across ACADIA Pharmaceuticals history.

ACADIA Pharmaceuticals Financial Ratios Chart

At present, ACADIA Pharmaceuticals' Book Value Per Share is projected to increase based on the last few years of reporting. The current year's Operating Cash Flow Per Share is expected to grow to 0.11, whereas Days Sales Outstanding is forecasted to decline to 48.85.

Price To Sales Ratio Days Sales Outstanding Operating Cash Flow Per Share Ev To Sales Inventory Turnover Pfcf Ratio

Add Fundamental

Price To Sales Ratio

Price to Sales Ratio is figured by comparing ACADIA Pharmaceuticals stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on ACADIA Pharmaceuticals sales, a figure that is much harder to manipulate than other ACADIA Pharmaceuticals multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Operating Cash Flow Per Share

A measure of the cash generated from a company's normal business operations per share, indicating how much cash is generated from a company's business operations on a per-share basis.

Ev To Sales

The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.

Inventory Turnover

A ratio showing how many times a company's inventory is sold and replaced over a period, indicating the efficiency of inventory management.

Most ratios from ACADIA Pharmaceuticals' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into ACADIA Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ACADIA Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For information on how to trade ACADIA Stock refer to our How to Trade ACADIA Stock guide.At present, ACADIA Pharmaceuticals' Book Value Per Share is projected to increase based on the last few years of reporting. The current year's Operating Cash Flow Per Share is expected to grow to 0.11, whereas Days Sales Outstanding is forecasted to decline to 48.85.

	2021	2022	2023	2024 (projected)
Payables Turnover	2.78	0.8	2.61	2.48
Days Of Inventory On Hand	150.28	238.26	285.89	153.81

Payables Turnover Days Of Inventory On Hand

ACADIA Pharmaceuticals fundamentals Correlations

	Price To Sales Ratio	Ptb Ratio	Days Sales Outstanding	Book Value Per Share	Free Cash Flow Yield	Operating Cash Flow Per Share	Capex To Depreciation	Pb Ratio	Ev To Sales	Free Cash Flow Per Share	Roic	Inventory Turnover	Net Income Per Share	Days Of Inventory On Hand	Payables Turnover	Capex To Revenue	Cash Per Share	Pocfratio	Interest Coverage	Capex To Operating Cash Flow	Pfcf Ratio	Days Payables Outstanding	Income Quality	Roe	Ev To Operating Cash Flow	Pe Ratio
Price To Sales Ratio		0.55	0.86	0.07	0.14	0.03	-0.02	0.55	1.0	0.04	-0.24	-0.29	0.06	0.35	0.52	0.93	-0.2	-0.17	0.1	-0.18	0.1	-0.34	0.14	-0.28	-0.17	0.02
Ptb Ratio	0.55		0.27	0.51	0.64	0.47	0.44	1.0	0.55	0.46	0.21	-0.01	0.44	-0.12	0.32	0.55	-0.29	0.2	0.5	0.18	-0.48	-0.01	-0.4	-0.28	0.2	-0.59
Days Sales Outstanding	0.86	0.27		-0.22	-0.17	-0.13	-0.09	0.27	0.86	-0.12	-0.36	-0.49	-0.08	0.61	0.69	0.86	-0.2	-0.24	-0.14	-0.31	0.24	-0.54	0.35	-0.17	-0.24	0.16
Book Value Per Share	0.07	0.51	-0.22		0.96	0.88	0.23	0.51	0.07	0.89	0.36	0.3	0.9	-0.35	-0.06	0.04	-0.67	0.02	0.98	0.12	-0.21	0.26	-0.11	-0.62	0.02	-0.29
Free Cash Flow Yield	0.14	0.64	-0.17	0.96		0.87	0.35	0.64	0.14	0.88	0.49	0.25	0.88	-0.33	0.03	0.1	-0.62	0.1	0.94	0.22	-0.33	0.25	-0.21	-0.47	0.1	-0.44
Operating Cash Flow Per Share	0.03	0.47	-0.13	0.88	0.87		0.34	0.47	0.03	1.0	0.47	0.09	0.99	-0.16	0.06	0.0	-0.81	0.26	0.93	0.34	-0.44	0.07	-0.28	-0.47	0.26	-0.51
Capex To Depreciation	-0.02	0.44	-0.09	0.23	0.35	0.34		0.44	-0.02	0.32	0.37	-0.25	0.29	0.16	0.24	0.05	-0.14	0.45	0.24	0.68	-0.59	0.38	-0.55	0.11	0.44	-0.65
Pb Ratio	0.55	1.0	0.27	0.51	0.64	0.47	0.44		0.55	0.46	0.21	-0.01	0.44	-0.12	0.32	0.55	-0.29	0.2	0.5	0.18	-0.48	-0.01	-0.4	-0.28	0.2	-0.59
Ev To Sales	1.0	0.55	0.86	0.07	0.14	0.03	-0.02	0.55		0.04	-0.24	-0.29	0.06	0.36	0.52	0.93	-0.2	-0.17	0.1	-0.18	0.1	-0.34	0.14	-0.28	-0.17	0.02
Free Cash Flow Per Share	0.04	0.46	-0.12	0.89	0.88	1.0	0.32	0.46	0.04		0.45	0.1	1.0	-0.16	0.07	0.0	-0.83	0.21	0.94	0.3	-0.38	0.07	-0.22	-0.5	0.21	-0.46
Roic	-0.24	0.21	-0.36	0.36	0.49	0.47	0.37	0.21	-0.24	0.45		0.1	0.43	-0.15	0.06	-0.34	0.0	0.33	0.31	0.3	-0.56	-0.07	-0.39	0.49	0.33	-0.67
Inventory Turnover	-0.29	-0.01	-0.49	0.3	0.25	0.09	-0.25	-0.01	-0.29	0.1	0.1		0.08	-0.93	-0.42	-0.22	0.15	0.04	0.21	-0.02	-0.02	0.09	-0.16	-0.11	0.04	0.03
Net Income Per Share	0.06	0.44	-0.08	0.9	0.88	0.99	0.29	0.44	0.06	1.0	0.43	0.08		-0.13	0.1	0.02	-0.85	0.18	0.95	0.25	-0.35	0.05	-0.17	-0.52	0.19	-0.43
Days Of Inventory On Hand	0.35	-0.12	0.61	-0.35	-0.33	-0.16	0.16	-0.12	0.36	-0.16	-0.15	-0.93	-0.13		0.54	0.28	-0.13	-0.11	-0.26	-0.13	0.14	-0.27	0.29	0.11	-0.11	0.07
Payables Turnover	0.52	0.32	0.69	-0.06	0.03	0.06	0.24	0.32	0.52	0.07	0.06	-0.42	0.1	0.54		0.45	-0.26	-0.3	0.0	-0.31	0.09	-0.56	0.33	0.02	-0.3	-0.16
Capex To Revenue	0.93	0.55	0.86	0.04	0.1	0.0	0.05	0.55	0.93	0.0	-0.34	-0.22	0.02	0.28	0.45		-0.2	-0.12	0.07	-0.14	0.1	-0.25	0.11	-0.34	-0.12	0.06
Cash Per Share	-0.2	-0.29	-0.2	-0.67	-0.62	-0.81	-0.14	-0.29	-0.2	-0.83	0.0	0.15	-0.85	-0.13	-0.26	-0.2		0.02	-0.79	-0.1	0.05	0.03	-0.11	0.72	0.02	0.12
Pocfratio	-0.17	0.2	-0.24	0.02	0.1	0.26	0.45	0.2	-0.17	0.21	0.33	0.04	0.18	-0.11	-0.3	-0.12	0.02		0.05	0.76	-0.9	0.02	-0.9	0.27	1.0	-0.75
Interest Coverage	0.1	0.5	-0.14	0.98	0.94	0.93	0.24	0.5	0.1	0.94	0.31	0.21	0.95	-0.26	0.0	0.07	-0.79	0.05		0.15	-0.22	0.21	-0.1	-0.67	0.05	-0.3
Capex To Operating Cash Flow	-0.18	0.18	-0.31	0.12	0.22	0.34	0.68	0.18	-0.18	0.3	0.3	-0.02	0.25	-0.13	-0.31	-0.14	-0.1	0.76	0.15		-0.71	0.46	-0.81	0.16	0.76	-0.59
Pfcf Ratio	0.1	-0.48	0.24	-0.21	-0.33	-0.44	-0.59	-0.48	0.1	-0.38	-0.56	-0.02	-0.35	0.14	0.09	0.1	0.05	-0.9	-0.22	-0.71		0.02	0.93	-0.3	-0.9	0.95
Days Payables Outstanding	-0.34	-0.01	-0.54	0.26	0.25	0.07	0.38	-0.01	-0.34	0.07	-0.07	0.09	0.05	-0.27	-0.56	-0.25	0.03	0.02	0.21	0.46	0.02		-0.17	-0.23	0.02	0.11
Income Quality	0.14	-0.4	0.35	-0.11	-0.21	-0.28	-0.55	-0.4	0.14	-0.22	-0.39	-0.16	-0.17	0.29	0.33	0.11	-0.11	-0.9	-0.1	-0.81	0.93	-0.17		-0.27	-0.9	0.81
Roe	-0.28	-0.28	-0.17	-0.62	-0.47	-0.47	0.11	-0.28	-0.28	-0.5	0.49	-0.11	-0.52	0.11	0.02	-0.34	0.72	0.27	-0.67	0.16	-0.3	-0.23	-0.27		0.27	-0.3
Ev To Operating Cash Flow	-0.17	0.2	-0.24	0.02	0.1	0.26	0.44	0.2	-0.17	0.21	0.33	0.04	0.19	-0.11	-0.3	-0.12	0.02	1.0	0.05	0.76	-0.9	0.02	-0.9	0.27		-0.75
Pe Ratio	0.02	-0.59	0.16	-0.29	-0.44	-0.51	-0.65	-0.59	0.02	-0.46	-0.67	0.03	-0.43	0.07	-0.16	0.06	0.12	-0.75	-0.3	-0.59	0.95	0.11	0.81	-0.3	-0.75

Click cells to compare fundamentals

ACADIA Pharmaceuticals Account Relationship Matchups

ACADIA Pharmaceuticals fundamentals Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Price To Sales Ratio	18.57	19.04	7.74	4.98	7.06	6.71
Ptb Ratio	9.01	13.41	6.93	6.43	11.88	12.47
Days Sales Outstanding	40.77	41.55	49.26	44.51	51.43	48.85
Book Value Per Share	4.75	3.99	3.37	2.48	2.64	2.77
Free Cash Flow Yield	(0.0242)	(0.0171)	(0.0338)	(0.0443)	(0.004552)	(0.00478)
Operating Cash Flow Per Share	(1.03)	(0.87)	(0.78)	(0.71)	0.1	0.11
Stock Based Compensation To Revenue	0.36	0.24	0.19	0.13	0.0914	0.0869
Capex To Depreciation	0.41	2.59	0.34	7.21	6.49	6.82
Pb Ratio	9.01	13.41	6.93	6.43	11.88	12.47
Ev To Sales	18.03	18.4	7.55	4.87	6.88	6.54
Free Cash Flow Per Share	(1.03)	(0.91)	(0.79)	(0.71)	(0.14)	(0.15)
Roic	(0.52)	(0.35)	(0.43)	(0.29)	(0.57)	(0.2)
Inventory Turnover	3.09	2.12	2.43	1.53	1.28	2.54
Net Income Per Share	(1.6)	(1.79)	(1.05)	(1.34)	(0.37)	(0.39)
Days Of Inventory On Hand	118.1	171.97	150.28	238.26	285.89	153.81
Payables Turnover	2.71	2.42	2.78	0.8	2.61	2.48
Sales General And Administrative To Revenue	1.19	0.96	0.88	0.82	0.54	0.51
Research And Ddevelopement To Revenue	0.71	0.72	0.49	0.7	0.48	0.46
Capex To Revenue	0.00333	0.0172	0.002317	0.0551	0.0496	0.0471
Cash Per Share	4.74	4.02	3.24	2.58	2.68	4.08
Pocfratio	(41.67)	(61.77)	(29.81)	(22.57)	307.1	322.45
Capex To Operating Cash Flow	(0.00747)	(0.0557)	(0.008929)	2.4	2.16	2.27
Pfcf Ratio	(41.36)	(58.51)	(29.55)	(22.57)	(219.68)	(208.7)
Days Payables Outstanding	134.51	150.85	131.12	457.63	140.02	113.25
Income Quality	0.68	0.64	0.48	0.53	(0.27)	(0.26)
Roe	(0.34)	(0.45)	(0.31)	(0.54)	(0.14)	(0.15)
Ev To Operating Cash Flow	(40.45)	(59.7)	(29.08)	(22.11)	299.23	314.19
Pe Ratio	(26.77)	(29.87)	(22.31)	(11.92)	(83.69)	(79.51)
Ev To Free Cash Flow	(40.15)	(56.55)	(28.83)	(22.11)	(214.05)	(203.35)
Earnings Yield	(0.0374)	(0.0335)	(0.0448)	(0.0839)	(0.0119)	(0.0125)
Intangibles To Total Assets	0.007519	0.003301	0.001416	0.0874	0.0787	0.0826
Net Debt To E B I T D A	0.24	0.55	0.75	0.98	1.94	2.03
Current Ratio	10.16	6.77	6.43	4.04	2.42	2.3
Tangible Book Value Per Share	4.73	3.98	3.37	2.48	2.24	2.35
Receivables Turnover	8.95	8.79	7.41	8.2	7.1	4.63
Graham Number	13.07	12.67	8.91	8.63	4.71	4.47
Shareholders Equity Per Share	4.75	3.99	3.37	2.48	2.64	2.77

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

When determining whether ACADIA Pharmaceuticals is a strong investment it is important to analyze ACADIA Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact ACADIA Pharmaceuticals' future performance. For an informed investment choice regarding ACADIA Stock, refer to the following important reports:

How To Invest In ACADIA

Details

Is ACADIA Stock a good investment?

Details

What is ACADIA Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For information on how to trade ACADIA Stock refer to our How to Trade ACADIA Stock guide.

You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ACADIA Pharmaceuticals. If investors know ACADIA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ACADIA Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

28.347

Earnings Share

0.78

Revenue Per Share

5.622

Quarterly Revenue Growth

0.183

Return On Assets

0.0872

The market value of ACADIA Pharmaceuticals is measured differently than its book value, which is the value of ACADIA that is recorded on the company's balance sheet. Investors also form their own opinion of ACADIA Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is ACADIA Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ACADIA Pharmaceuticals' market value can be influenced by many factors that don't directly affect ACADIA Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between ACADIA Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if ACADIA Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ACADIA Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Price To Sales Ratio	Dividend Yield
Ptb Ratio	Days Sales Outstanding
Book Value Per Share	Free Cash Flow Yield
Invested Capital	Operating Cash Flow Per Share
Average Payables	Stock Based Compensation To Revenue
Capex To Depreciation	Pb Ratio
Ev To Sales	Free Cash Flow Per Share
Roic	Inventory Turnover
Net Income Per Share	Days Of Inventory On Hand
Payables Turnover	Sales General And Administrative To Revenue
Average Inventory	Research And Ddevelopement To Revenue
Capex To Revenue	Cash Per Share
Pocfratio	Interest Coverage
Payout Ratio	Capex To Operating Cash Flow
Pfcf Ratio	Days Payables Outstanding
Net Current Asset Value	Income Quality
Roe	Tangible Asset Value
Ev To Operating Cash Flow	Pe Ratio
Return On Tangible Assets	Ev To Free Cash Flow
Earnings Yield	Intangibles To Total Assets
Net Debt To E B I T D A	Current Ratio
Tangible Book Value Per Share	Receivables Turnover
Graham Number	Shareholders Equity Per Share
Debt To Equity	Capex Per Share
Graham Net Net	Average Receivables
Revenue Per Share	Interest Debt Per Share
Debt To Assets	Enterprise Value Over E B I T D A
Short Term Coverage Ratios	Price Earnings Ratio
Operating Cycle	Price Book Value Ratio
Price Earnings To Growth Ratio	Days Of Payables Outstanding
Dividend Payout Ratio	Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio	Pretax Profit Margin
Ebt Per Ebit	Operating Profit Margin
Effective Tax Rate	Company Equity Multiplier
Long Term Debt To Capitalization	Total Debt To Capitalization
Return On Capital Employed	Debt Equity Ratio
Ebit Per Revenue	Quick Ratio
Dividend Paid And Capex Coverage Ratio	Net Income Per E B T
Cash Ratio	Cash Conversion Cycle
Operating Cash Flow Sales Ratio	Days Of Inventory Outstanding
Days Of Sales Outstanding	Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios	Price To Book Ratio
Fixed Asset Turnover	Capital Expenditure Coverage Ratio
Price Cash Flow Ratio	Enterprise Value Multiple
Debt Ratio	Cash Flow To Debt Ratio
Price Sales Ratio	Return On Assets
Asset Turnover	Net Profit Margin
Gross Profit Margin	Price Fair Value
Return On Equity

ACADIA Historical Financial Ratios

About ACADIA Financial Ratios Analysis

ACADIA Pharmaceuticals Financial Ratios Chart

Price To Sales Ratio

Operating Cash Flow Per Share

Ev To Sales

Inventory Turnover

ACADIA Pharmaceuticals fundamentals Correlations

ACADIA Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

ACADIA Pharmaceuticals fundamentals Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Ev To Sales	+ 1.0	Price To Sales Ratio
Pb Ratio	+ 1.0	Ptb Ratio
Free Cash Flow Per Share	+ 1.0	Operating Cash Flow Per Share
Net Income Per Share	+ 1.0	Free Cash Flow Per Share
Ev To Operating Cash Flow	+ 1.0	Pocfratio
Net Income Per Share	+ 0.99	Operating Cash Flow Per Share

Days Of Inventory On Hand	- 0.93	Inventory Turnover
Ev To Operating Cash Flow	- 0.9	Income Quality
Ev To Operating Cash Flow	- 0.9	Pfcf Ratio
Income Quality	- 0.9	Pocfratio
Pfcf Ratio	- 0.9	Pocfratio
Cash Per Share	- 0.85	Net Income Per Share